Clinical and Experimental Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Via Franco Gallini 2, Aviano (PN), 33081, Italy.
Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via Giorgieri 1, 34127, Trieste, Italy.
Anal Bioanal Chem. 2021 Feb;413(4):1225-1236. doi: 10.1007/s00216-020-03087-5. Epub 2021 Jan 6.
In this work, a surface plasmon resonance (SPR)-based assay for the quantification of antineoplastic drug irinotecan in human plasma samples has been developed for the first time. The selective binding of irinotecan with an aptamer receptor, operating in human plasma, allowed to set-up a novel analytical methodology to detect the drug in the analytical range of interest by using SPR as detection technique. After hybridizing the aptamer to the sensing platform and optimizing the sample preparation procedure, a quantitative assay was validated according to FDA regulatory guidelines. The analytical working range was found between 100 and 7500 ng mL with negligible interferences from plasma components and co-medication associated with the administration of irinotecan. The utility of the new SPR assay was confirmed by analyzing plasma samples in parallel with LC-MS as reference technique, providing a new analytical tool for the therapeutic drug monitoring of irinotecan in patients under chemotherapy regimens.
本工作首次开发了一种基于表面等离子体共振（SPR）的分析方法，用于定量检测人血浆样品中的抗肿瘤药物伊立替康。伊立替康与人血浆中的适体受体选择性结合，允许通过 SPR 作为检测技术，在感兴趣的分析范围内建立一种检测该药物的新分析方法。在将适体杂交到传感平台并优化样品制备程序后，根据 FDA 监管指南验证了定量分析方法。分析工作范围在 100 和 7500ng/mL 之间，血浆成分和与伊立替康给药相关的联合用药几乎没有干扰。通过与 LC-MS 作为参考技术平行分析血浆样品，证实了新的 SPR 分析方法的实用性，为化疗方案下伊立替康的治疗药物监测提供了一种新的分析工具。
